Trials / Terminated
TerminatedNCT03943550
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7049665 | Multiple ascending doses of RO7049665 will be administered SC. |
| DRUG | Placebo | Matching placebo will be administered SC. |
Timeline
- Start date
- 2019-05-13
- Primary completion
- 2021-07-22
- Completion
- 2021-07-22
- First posted
- 2019-05-09
- Last updated
- 2024-02-15
- Results posted
- 2024-02-15
Locations
6 sites across 5 countries: United States, Georgia, Hungary, Moldova, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03943550. Inclusion in this directory is not an endorsement.